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Summary  Atrial  ﬁbrillation  (AF)  is  a  common  and  serious  condition  in  the  elderly.  AF  affects
between  600,000  and  one  million  patients  in  France,  two-thirds  of  whom  are  aged  above  75
years. AF  is  a  predictive  factor  for  mortality  in  the  elderly  and  a  major  risk  factor  for  stroke.
Co-morbidities  are  frequent  and  worsen  the  prognosis.  The  management  of  AF  in  the  elderly
should involve  a  comprehensive  geriatric  assessment  (CGA),  which  analyses  both  medical  and
psychosocial  elements,  enabling  evaluation  of  the  patient’s  functional  status  and  social  situa-
tion and  the  identiﬁcation  of  co-morbidities.  The  CGA  enables  the  detection  of  ‘‘frailty’’  using
screening  tools  assessing  cognitive  function,  risk  of  falls,  nutritional  status,  mood  disorders,
autonomy  and  social  environment.  The  objectives  of  AF  treatment  in  the  elderly  are  to  prevent
AF complications,  particularly  stroke,  and  improve  quality  of  life.  Speciﬁc  precautions  for  treat-
ment must  be  taken  because  of  the  co-morbidities  and  age-related  changes  in  pharmacokinetics
or pharmacodynamics.  Preventing  AF  complications  relies  mainly  on  anticoagulant  therapy.  Anti-
coagulants  are  recommended  in  patients  with  AF  aged  75  years  or  above  after  assessing  the
bleeding risk  using  the  HEMORR2HAGES  or  HAS-BLED  scores.  Novel  oral  anticoagulants  (NOACs)
are promising  treatments,  especially  due  to  a  lower  risk  of  intracerebral  haemorrhage.  How-
ever, their  prescriptions  should  take  into  account  renal  function  (creatinine  clearance  assessed
with Cockcroft  formula)  and  cognitive  function  (for  adherence  to  treatment).  Studies  including
frail patients  in  ‘‘real  life’’  are  necessary  to  evaluate  tolerance  of  NOACs.  Management  of  AF
also involves  the  treatment  of  underlying  cardiomyopathy  and  heart  rate  control  rather  than
a rhythm-control  strategy  as  ﬁrst-line  therapy  for  elderly  patients,  especially  if  they  are  pau-
cisymptomatic.  Antiarrhythmic  drugs  should  be  used  carefully  in  elderly  patients  because  of
the frequency  of  metabolic  abnormalities  and  higher  risk  of  drug  interactions  and  bradycardia.
© 2013  Elsevier  Masson  SAS.  All  rights  reserved.
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Résumé  La  ﬁbrillation  atriale  (FA)  constitue  un  problème  de  santé  publique  avec  entre
600 000  à  un  million  de  patients  concernés  en  France  dont  les  deux-tiers  sont  âgés  de  plus  de
75 ans.  La  FA  majore  de  risque  mortalité  et  représente  un  facteur  majeur  de  risque  d’accident
vasculaire  cérébral  ischémique  (AVC).  Chez  la  personne  âgée  en  FA,  les  comorbidités  sont
fréquentes  et  aggravent  le  pronostic.  La  prise  en  charge  de  la  FA  du  sujet  âgé  doit  s’accompagner
d’une évaluation  gériatrique  standardisée  (EGS)  qui  apprécie  les  éléments  médicaux,  psychoso-
ciaux et  permet  une  évaluation  fonctionnelle  du  patient  et  de  sa  situation  sociale.  Elle  conduit
à identiﬁer  certaines  comorbidités  ou  syndromes  gériatriques  (troubles  cognitifs,  chutes,  dénu-
trition, dépression).  Pour  rendre  l’évaluation  gériatrique  plus  facile  dans  la  pratique  clinique,
des tests  courts  de  screening  sont  proposés,  ils  peuvent  être  complétés  par  une  exploration
plus complète  réalisée  par  des  équipes  spécialisées  de  gériatrie.  Les  objectifs  généraux  du
traitement restent  applicables  au  sujet  âgé  :  prévention  des  complications  en  particulier  l’AVC,
amélioration  de  la  qualité  de  vie,  réduction  de  la  mortalité  et  des  hospitalisations.  Des  précau-
tions particulières  d’utilisation  des  médicaments  sont  nécessaires  en  raison  des  comorbidités
et de  modiﬁcations  pharmacocinétiques  ou  pharmacodynamiques  liées  au  vieillissement.  La
prévention  des  complications  repose  essentiellement  sur  le  traitement  anticoagulant.  Les  anti-
coagulants  sont  recommandés  après  75  ans  en  cas  de  FA  après  évaluation  du  risque  hémorragique
en utilisant  les  scores  HEMORR2HAGES  ou  HAS-BLED.  Les  nouveaux  anticoagulants  sont  promet-
teurs pour  la  prise  en  charge  des  malades  âgés  en  FA  non  valvulaire,  en  particulier  en  raison  du
moindre risque  d’hémorragie  cérébrale.  Toutefois,  leur  utilisation  nécessite  la  prise  en  compte
la fonction  rénale  (clairance  de  la  créatinine  selon  la  formule  de  Cockcroft)  et  du  fonction-
nement cognitif  (observance  thérapeutique).  La  réalisation  d’études  menées  spéciﬁquement
dans les  populations  de  patients  très  âgés  polypathologiques  est  nécessaire  pour  évaluer  leur
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tolérance  en  situation  de  « vie  réelle  ».  La  prise  en  charge  comprend  aussi  le  traitement  de
la cardiopathie  sous-jacente  et  la  gestion  du  rythme  cardiaque.  Chez  les  personnes  âgées,  la
stratégie du  contrôle  de  fréquence  cardiaque  doit  être  privilégiée  par  rapport  à  celle  du  contrôle
du rythme  dans  la  majorité  des  cas.  L’emploi  des  anti-arythmiques  doit  être  prudent  du  fait  des
anomalies  métaboliques  fréquentes  et  d’un  plus  grand  risque  d’interaction  médicamenteuse  et
de bradycardie.
© 2013  Elsevier  Masson  SAS.  Tous  droits  réservés.
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Figure 1. Classiﬁcation of atrial ﬁbrillation. 1: an episode thatDeﬁnition
Atrial  ﬁbrillation  (AF)  is  an  arrhythmia  characterized  by  dis-
organized  atrial  activation  with  consequent  deterioration  of
atrial  mechanical  function  [1].  Clinically,  AF  is  suspected  in
case  of  irregularity  in  pulse  and  heart  rate.  The  diagnosis  is
made  by  means  of  an  electrocardiogram  (ECG)  showing  the
absence  of  P  wave  undulating  baseline  and  irregular  ventri-
cular  response  when  atrioventricular  conduction  is  normal.
The  underlying  mechanism  usually  involves  multiple
micro—re-entry  circuits.  In  some  cases,  AF  is  due  to  abnor-
mal  ectopic  foci  located  in  the  pulmonary  veins  [2].  Other
atrial  arrhythmias  can  occur  in  patients  with  AF,  such  as
atrial  tachycardia  or  atrial  ﬂutter.
Classiﬁcation
Several  classiﬁcations  of  AF  have  been  proposed,  based
on  ECG  features  or  clinical  presentation.  The  ‘‘three-P’’
classiﬁcation  is  consensual:  paroxysmal,  persistent  and  per-
manent.  AF  is  paroxysmal  if  it  is  self-terminating,  usually
within  48  hours;  AF  paroxysms  may  continue  for  up  to  7  days.
AF  is  persistent  if  the  episode  lasts  for  more  than  7  days
and  is  not  terminated  spontaneously.  AF  is  permanent  if  all
recorded  ECGs  show  AF  over  an  extended  period  (in  gen-
eral  >  1  year).  Persistent  AF  becomes  permanent  AF  when
cardioversion  is  not  attempted  or  is  unsuccessful.
When  a  patient  is  seen  for  the  ﬁrst  time  for  AF  and
the  arrhythmia  was  not  previously  known,  it  is  called
ﬁrst-detected  AF.  The  evolution  of  ﬁrst-detected  AF  to
a  paroxysmal,  persistent  or  permanent  pattern  is  unpre-
dictable  (Fig.  1).  Paroxysmal  AF  is  often  recurrent.
Epidemiology
AF  constitutes  a  public  health  problem.  It  affects  between
600,000  and  1  million  patients  in  France,  two-thirds  of  whom
(i.e.  400,000  to  660,000  people)  are  aged  above  75  years  [3].
The  average  annual  cost  per  patient  with  AF  is  estimated  to
be  3000  euros  [4].  The  total  cost  of  the  disease  is  about  2.5
billion  euros,  half  of  which  is  related  to  hospital  expenses.
The  prevalence  of  AF  increases  with  age;  it  doubles  each
decade  after  the  age  of  50  years  (Fig.  2)  [5—14]  and  increases
from  less  than  0.5%  for  those  aged  40—50  years  to  10—20%
for  those  aged  80  years  or  above  [8,10,15].  Thus,  70%  of
AF  patients  are  aged  75  years  or  above  [3].  This  prevalence
l
m
a
bs  probably  underestimated  because  the  methods  used  in
pidemiological  studies  poorly  detect  paroxysmal  AF  [16].
The  prevalence  of  AF  is  higher  among  men  than  women.
owever,  the  number  of  women  with  AF  appears  to  be  higher
ue  to  the  longer  life  expectancy  for  women  [17].  Lastly,  AF
revalence  has  increased  in  the  past  decades  independent  of
opulation  ageing  [8,10,18].  In  the  USA,  the  age-  and  sex-
djusted  AF  incidence  was  3.04  per  1000  person-years  in
981,  increasing  to  3.68  in  2000  [19].  Extrapolation  to  the
rench  population  yields  a  number  of  200,000  new  cases  per
ear.  Based  on  these  elements,  the  number  of  patients  with
F  is  expected  to  double  or  triple  in  the  next  decades.
etiologies and co-morbidities
ardiac  ageing  is  often  associated  with  myocardial  ﬁbro-
is  and  atrial  dilation,  which  favour  the  occurrence  of  AF.
ll  cardiac  diseases  (in  particular  ischaemic,  valvular  or
ypertensive  heart  diseases)  may  be  complicated  by  AF,
specially  at  an  advanced  stage  of  their  evolution.  Main
ardiovascular  risk  factors  are  also  associated  with  the  risk
f  AF  [12].  Among  these  factors,  age  and  hypertension
lay  a  leading  role.  Lastly,  a  search  for  an  extracardiac
ause,  such  as  bronchopneumonia,  chronic  obstructive  pul-
onary  disease  (COPD),  pulmonary  embolism,  iatrogenic
vent,  hypokalaemia,  hyperthyroidism  or  sleep  apnoea  syn-
rome,  should  be  carried  out  systematically.asts less than or 7 days (often < 24 hours); 2: an episode that lasts
ore than 7 days; 3: cardioversion is unsuccessful or it is not
ttempted. Note that paroxysmal and persistent ﬁbrillations may
e recurrent.
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Figure 2. Prevalence of atrial ﬁbrillation stratiﬁed by age and
sex in published studies since 1991: 1: [9]; 2: [8]; 3: [13]; 4: [12];
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apnoea: [11]; 6: [10]; 7: [6]; 8: [5]; 9: [7]; 10: [14].
In  elderly  people,  co-morbidities  are  frequent  and  worsen
he  prognosis  of  AF.  They  can  be  the  cause  or  the  conse-
uence  of  AF  and  their  management  is  a  major  therapeutic
bjective.
ypertension
ypertension  is  the  most  frequent  co-morbidity  factor  asso-
iated  with  AF  in  the  elderly,  with  a  prevalence  varying
rom  40%  to  70%  [20].  Hypertension  signiﬁcantly  raises  the
ncidence  of  AF  and  thromboembolic  events  [15,21]. Recent
orks  [22]  demonstrate  the  role  of  pulse  pressure  as  a  pre-
ictive  factor  for  AF;  they  highlight  the  impact  of  arterial
geing  on  left  ventricular  hypertrophy  in  the  mechanisms  of
lectrophysiological  alterations.
R
cO.  Hanon  et  al.
Blood  pressure  control  seems  to  reduce  the  incidence
f  AF  [23,24].  Several  meta-analyses  [25,26]  suggest  a
rotective  effect  of  renin-angiotensin  system  blockers
angiotensin-converting  enzyme  inhibitors  or  angiotensin  II
eceptor  blockers)  on  AF  occurrence.  However,  this  class-
ffect  on  reducing  the  incidence  of  AF  recurrences  has  not
een  conﬁrmed  in  a  randomized  trial  [27].  In  any  case,  blood
ressure  control  in  patients  with  AF  and  hypertension  is  a
ajor  goal  for  the  prevention  of  complications,  particularly
erebral  strokes.
eart failure
he  occurrence  of  heart  failure  modiﬁes  the  prognosis  of
F,  with  an  increased  risk  of  mortality  and  stroke  [28],  even
n  cases  of  heart  failure  with  preserved  ejection  fraction.
fter  the  age  of  75  years,  the  prevalence  of  AF  is  about  40%
n  patients  with  heart  failure  [29,30].
The  interaction  between  AF  and  heart  failure  is  com-
lex  and  is  a vicious  circle  [31].  AF  favours  heart  failure
nd  heart  failure  raises  the  risk  of  AF  development.
eart  failure  increases  atrial  pressures  and  volumes  and
hus  increases  atrial  stretch;  it  also  leads  to  neurohor-
onal  activation,  which  generates  electrical  and  anatomical
emodelling  responsible  for  modiﬁcations  of  atrial  electro-
hysiological  properties.  On  the  other  hand,  AF  favours
eart  failure  because  of  the  loss  of  atrial  systole  leading
o  a  decrease  in  diastolic  ventricular  ﬁlling.  Lastly,  tachy-
ardia  and  irregularity  of  ventricular  cycles  contribute  to
lterations  of  cardiac  output.
oronary heart disease
oronary  heart  disease  is  a  risk  factor  for  AF  [15,21];  it
lso  presents  a  risk  factor  for  stroke  [20]  in  the  presence
f  AF.  Particularly,  the  acceleration  of  heart  rate  and  the
rregularity  of  cycles  increase  myocardial  oxygen  consump-
ion  and  may  alter  coronary  output.
iabetes mellitus
iabetes  mellitus  constitutes  a  risk  factor  for  AF  and
 risk  factor  for  stroke  in  the  presence  of  AF  [21,32].
he  explanatory  factors  of  this  association  are  numer-
us:  arterial  hypertension,  coronary  heart  disease,  altered
ympathetic  tone,  ‘‘direct  toxicity’’  of  glucose  on  atrial
tructure,  deterioration  of  diastolic  function,  alteration  of
trial  endothelial  function  and  more  frequent  acute  stress
ituations  (infections,  electrolyte  anomalies,  renal  failure,
tc.).
besity
besity  is  a  risk  factor  for  AF  [33]  due  to  left  atrial  dilation,
resence  of  high  blood  pressure  or  ventricular  hypertrophy.
espiratory insufﬁciency, COPD and sleepespiratory  diseases,  particularly  sleep  apnoea,  are  asso-
iated  with  AF  due  to  oxygen  desaturation  episodes,
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Table  1  CHADS2 and  CHA2DS2-VASc  scores.
CHADS2
score
CHA2DS2-VASc
score
Items
Age  ≥  75  years  1  2
Age  65—74  years  0  1
Arterial  hypertension  1  1
Diabetes  1  1
Heart  failure  or  left
ventricular  dysfunction
1  1
Previous  stroke  or  transient
ischaemic  attack
2 2
Female  sex  (if  age  >  65  years)  1
Vascular  diseases  (prior
myocardial  infarction,
peripheral  artery  disease,
aortic  plaque)
1
Anticoagulation
No  therapy  0
Aspirina 0
Aspirina or  anticoagulant
therapy
1
Anticoagulant  therapy  ≥  2  1  or  ≥  2
Adapted from Camm et al. [43,65].
a
Figure 3. Risk of atrial ﬁbrillation-related stroke according to
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ﬂuctuations  in  sympathetic  activity  or  modiﬁcations  of
intrathoracic  pressure  [34].
Prognosis and outcome
Mortality
AF  is  a  predictive  factor  for  mortality.  Several  observational
studies  show  an  increase  in  the  risk  of  death  from  50%  to
90%  in  patients  with  AF  compared  with  subjects  of  the  same
age  in  sinus  rhythm  [35,36].  In  the  Euro  Heart  Survey  (mean
age,  66  years),  the  1-year  mortality  of  patients  with  AF  was
5%  (50%  of  deaths  were  due  to  cardiovascular  causes)  [37].
In  the  BAFTA  study  (subjects  aged  >  75  years),  the  annual
death  rate  was  8%  (50%  of  deaths  were  due  to  cardiovascu-
lar  causes)  [38].  The  risk  is  higher  among  women,  especially
when  cardiomyopathy  or  underlying  heart  failure  is  asso-
ciated.  Nevertheless,  the  increase  in  AF-related  mortality
seems  to  lower  beyond  the  age  of  75  years  due  to  overmor-
tality  related  to  other  causes  [39].
Stroke
Stroke  presents  the  main  AF  complication  and  accounts  for
85%  of  embolic  accidents  due  to  AF.  The  annual  incidence  of
stroke  is  similar  in  paroxysmal  AF  and  permanent  AF,  vary-
ing  from  1.5%  to  3.3%  [37,40].  The  main  risk  factors  for  the
occurrence  of  stroke  in  AF  patients  [41]  are  included  in  the
CHADS2 score  [42]  (Table  1):  congestive  heart  failure,  hyper-
tension,  age  75  years  or  above,  diabetes  (one  point  for  each
item)  and  prior  stroke  or  transient  ischaemic  attack  (two
t
t
t
age.
dapted from Wolf et al. [40].
oints).  This  score  allows  the  evaluation  of  thromboembolic
isk  in  AF.
The  European  Society  of  Cardiology  (ESC)  guidelines  2012
ocused  update  [43]  recommended  use  of  the  CHA2DS2-VASc
isk  score  [44]  (Table  1) to  assess  stroke  risk  in  patients  with
F.  This  score  includes  three  further  risk  factors:  female
ex,  age  65—74  years  and  history  of  cardiovascular  diseases
Table  1).
The  risk  of  stroke  increases  with  age,  which  is  an  item  in
he  CHADS2 score  (≥  75  years)  as  well  as  in  the  CHA2DS2-VASc
core  (moderate  risk  from  65—74  years,  high  risk  if  aged  ≥  75
ears).  AF  is  a  major  risk  factor  for  stroke  in  the  elderly:  the
isk  of  stroke  related  to  AF  is  2%  for  age  less  than  70  years,
4%  for  age  80—89  years  and  35%  for  age  above  90  years
Fig.  3)  [40].  In  the  elderly,  80%  of  strokes  are  ischaemic
nd  20%  are  haemorrhagic  [40].
AF-related  strokes  seem  to  be  more  severe  than  those
nrelated  to  AF,  with  an  increased  30-day  mortality  of
7—57%,  2-fold  mortality  and  recurrences  at  1  year  and  more
evere  disability  at  3  months  (75%  of  patients  with  AF  are
ependent  compared  with  36%  of  those  without  AF)  [45—48].
ther cardiovascular events
F  is  associated  with  a  high  annual  incidence  of  cardiovascu-
ar  events.  In  the  Euro  Heart  Survey  [37],  11%  of  AF  patients
ad  heart  failure  (one-third  of  whom  had  new  onset  heart
ailure),  6%  had  coronary  events  and  49%  of  cases  needed
ospitalization,  75%  for  cardiovascular  causes.
ospitalizations
n  France  in  2008,  an  analysis  of  the  database  of  the  elec-
ronic  medical  record  system  (PMSI)  showed  that  AF  was
he  main  diagnosis  in  84,000  hospitalizations  and  one  of
he  associated  diagnoses  in  349,000  hospitalizations.  This
ccounts  for  a  total  of  412,000  patients  and  a  total  of
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10,198  hospitalizations  [3].  The  number  of  AF  hospitaliza-
ions  has  increased  by  26%  over  a  3-year  period.  Most  of
hese  patients  (92%)  were  aged  60  years  or  above.  Patholo-
ies  associated  with  AF  were  hypertension,  cardiac  diseases,
eart  failure,  stroke,  syncope  and  renal  dialysis.  The  death
ate  among  these  patients  was  5.6%.  It  has  been  estimated
hat  each  year,  41%  of  AF  patients  are  hospitalized;  of  these,
%  are  hospitalized  for  a  direct  AF-related  problem.
ognitive disorders
everal  epidemiological  studies  suggest  that  AF  increases
he  risk  of  cognitive  disorders  and  dementias  [5,49,50].
 recent  meta-analysis,  including  21  studies  and  95,427
ubjects,  showed  a  signiﬁcant  association  between  AF  and
ognitive  impairment  or  dementia  (relative  risk  1.40,  95%
I  1.19—1.64),  both  in  patients  with  or  without  history  of
troke  [51].  This  cognitive  alteration  could  be  due  to  com-
on  risk  factors  (hypertension,  diabetes),  the  occurrence
f  cerebral  microemboli  or  ﬂuctuations  of  cerebral  per-
usion.  Cognitive  disorders  in  elderly  patients  with  AF  must
e  detected  and  assessed  because  of  their  impact  on  progno-
is,  autonomy,  understanding  instructions  and  adherence  to
reatment  (cf.  paragraph  on  comprehensive  geriatric  assess-
ent  [CGA]).
uality of life
lderly  patients  with  AF  have  a  poorer  quality  of  life
ompared  with  other  people  of  the  same  age.  Rhythm-
r  rate-control  strategies  allow  signiﬁcant  improvement  in
uality  of  life  [52].
iagnosis
linical presentations
n  the  elderly,  AF  is  often  asymptomatic  and  an  inciden-
al  ﬁnding  [53,54].  Palpitations  are  less  frequent  in  elderly
atients  compared  with  younger  adults  [55].  When  present,
F  symptoms  are  diverse  [56,57]:  dyspnoea,  palpitations,
horacic  pain,  faintnesses,  falls,  syncope,  asthenia,  anxiety,
tc.  AF  can  also  be  discovered  when  a  complication,  such  as
n  embolic  accident  or  heart  failure,  occurs.
AF  in  the  elderly  is  often  of  acute  onset  during  the  course
f  stress  secondary  to  an  infectious  episode  (particularly
ronchopneumonia),  a  surgical  procedure  and  cardiac  or
espiratory  decompensation.  The  occurrence  of  AF  in  the
lderly  indicates  a  high  probability  of  an  underlying  cardio-
ascular  disease  and  a  higher  risk  of  AF  recurrence  compared
ith  that  in  younger  people.
linical assessment
he  aim  of  the  clinical  assessment  is  to  deﬁne  the  type  of
F  (paroxysmal,  persistent  or  permanent),  to  specify  the
llness  history  and  to  evaluate  symptoms,  trigger  factors,
ardiovascular  diseases,  complications,  co-morbidities  and
urrent  therapeutics.
T
T
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istory  of  atrial  ﬁbrillation
he  history  of  AF  in  elderly  patients  is  often  difﬁ-
ult  to  reconstitute;  questioning  the  patient’s  family
ircle  and/or  general  practitioner  may  be  necessary.  A
rigger  factor  must  be  systematically  sought:  infectious
pisode,  cardiac  or  respiratory  decompensation,  myocardial
schaemia,  electrolyte  disorders  (hypokalaemia),  hyper-
hyroidism,  iatrogenic  factors,  diuretics,  theophylline,
albutamol,  etc.
entricular  rate
earching  for  pulse  irregularity  should  be  done  systemati-
ally.  Pulse  palpation  has  a  high  sensitivity  but  low  speciﬁcity
or  AF  [54,58]. The  diagnosis  of  AF  must  be  conﬁrmed  by
n  ECG.  A  very  rapid  ventricular  rate  suggests  an  associated
xtracardiac  factor,  especially  in  case  of  well-tolerated  per-
anent  AF.  Bradyarrhythmia  may  be  due  to  an  iatrogenic
ffect  (antiarrhythmic  drugs,  digitalis,  calcium  channel
ntagonists,  inhibitors  of  cholinesterase,  beta-blockers)  or
n  associated  conduction  disorder.
omprehensive  assessment  of  the  elderly  subject
ith atrial  ﬁbrillation
t  is  necessary  to  look  for  co-morbidities  and  complications
f  AF,  evaluate  the  thromboembolic  and  haemorrhagic  risks
nd  carry  out  a  CGA.
iagnostic tests
welve-lead  ECG
 12-lead  ECG  is  indispensable  to  conﬁrm  the  diagnosis
Table  2).  When  paroxysmal  AF  is  suspected,  repeated  ECG
onitoring  or  long-term  recordings  should  be  considered.
hen  AF  is  associated  with  a  slow  ventricular  rate,  an  atrio-
entricular  block  should  be  suspected.
hest  X-ray
 chest  X-ray  allows  heart  size  measurement  and  analysis  of
he  pulmonary  parenchyma  (interstitial  oedema,  pneumo-
ia,  pulmonary  sequelae);  it  helps  detection  of  interstitial
neumonia  due  to  long-term  amiodarone  therapy.
mbulatory  long-term  ECG  recordings
mbulatory  long-term  ECG  recordings  can  be  useful  to  con-
rm  paroxysmal  AF  or  in  case  of  symptoms  that  can  be
elated  to  a  slow  ventricular  rate  (syncope,  faintness)  or
 very  rapid  ventricular  rate  despite  treatment.
ransthoracic  echocardiography
ransthoracic  echocardiography  is  recommended  in  all  AF
atients;  it  is  used  to  detect  ventricular,  valvular  and  atrial
isease.  The  presence  or  absence  of  an  underlying  cardiomy-
pathy  is  important  for  the  choice  of  antiarrhythmic  and
ntithrombotic  drugs.ransoesophageal  echocardiography
ransoesophageal  echocardiography  is  the  only  examination
hat  enables  the  analysis  of  intra-atrial  thrombosis;  it  is,
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Table  2  Diagnostic  tests  in  elderly  people  with  atrial  ﬁbrillation  (AF).
Tests  Indication  Awaited  result
ECG  Systematic  Diagnosis  of  AF
ECG  Holter  recording  Non-systematic  unless  syncope,
faintness,  unexplained  heart  failure
Searching  for  bradycardia,  heart  pauses,
rapid  ventricular  rate
Transthoracic  echocardiography Systematic  Searching  for  heart  disease,  left  atrium
dimensions,  left  ventricular  function
Transoesophageal
echocardiography
Non-systematic  unless  rapid
cardioversion  is  indicated
Intracavitary  thrombus
Chest  X-ray  Non-systematic  Cardiomegaly,  signs  of  pulmonary
oedema
BNP,  troponin  Non-systematic
Blood  cell  count,  serum
electrolytes,  creatinine,
glycaemia,  haemostasis  test
Systematic  Searching  for  anaemia,  creatinine
clearance  calculation,  potassium
disorders,  diabetes,  haemostasis  disorder
Thyroid-stimulating  hormone  Systematic  Hyperthyroidism
Serum  digoxin  level  Non-systematic  unless  overdose  is
suspected
Liver  function  tests,  CRP  Non-systematic  unless  clinical  suspicions
BNP: B-type natriuretic protein; CRP: C-reactive protein; ECG: electrocardiogram.
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chowever,  rarely  carried  out  in  the  elderly.  The  two  main  indi-
cations  are:  reversion  to  sinus  rhythm  without  prior  effective
anticoagulation  (for  at  least  3  weeks);  and  a  search  for  the
underlying  cause  in  case  of  recurrent  stroke  or  transient
ischaemic  attack  of  unknown  aetiology.
Blood  tests
A  systematic  work-up  must  be  carried  out:  complete  blood
count,  international  normalized  ratio  (INR)  for  patients  on
a  vitamin  K  antagonist,  partial  thromboplastin  time,  serum
electrolytes,  creatinine  (with  its  clearance  calculated  by
the  Cockcroft  formula),  glycaemia  and  thyroid-stimulating
hormone.  According  to  the  clinical  picture,  the  following
tests  can  be  added:  troponin  assay,  C-reactive  protein,  liver
function  tests,  serum  albumin  and  urine  test  strip  ±  urine
culture.  This  work-up  is  necessary  for  the  detection  of  trig-
ger  factors  and  for  therapeutic  management.
Comprehensive geriatric assessment
The  management  of  AF  in  an  elderly  subject  should  involve
a  CGA,  which  analyses  both  medical  and  psychosocial  ele-
ments,  enabling  evaluation  of  the  patient’s  functional  status
and  social  situation  and  identiﬁcation  of  co-morbidities.
The  CGA  enables  the  detection  of  ‘‘frailty’’,  which
is  characterized  by  decreased  physiological  adaptation  to
stress  or  environmental  changes,  whether  associated  with
organ  failure.  Short  screening  tools  are  proposed  to  make
CGA  easier  and  quicker  to  complete  in  clinical  practice.  If
screening  tests  are  abnormal,  an  intensive  exploration  by
t
o
3
tpecialized  geriatric  teams  must  be  launched  (Table  3).  The
rincipal  elements  of  the  CGA  are  outlined  below.
ssessment of cognitive function
valuation  of  cognitive  function  is  important  in  elderly  AF
atients  for  several  reasons:  it  assesses  the  quality  of  the
nformation  obtained  from  the  subjects  (regarding  memory
isorders  and  the  absence  of  functional  complaint  in  anosog-
osic  patients),  the  ability  to  understand  instructions  and
he  potential  for  therapeutic  observance  and  adherence  to
reatment,  particularly  antithrombotics.  Medical  history  and
linical  examination  are  not  enough  to  detect  mild  cogni-
ive  impairment  (MCI);  only  cognitive  assessment  using  a  test
an  reveal  MCI.  The  Mini  Mental  State  Examination  (MMSE)
59]  is  a  simple  and  brief  standardized  30-point  test  that
s  used  for  screening  cognitive  disorders  (Appendix  1).  The
hreshold  value  depends  on  the  age  and  educational  level
f  the  patient.  A  score  greater  than  27  is  considered  nor-
al.  A  score  less  than  24  is  abnormal  and  should  lead  to
 more  detailed  evaluation  of  the  cognitive  functions  in  a
pecialized  setting.  A  score  between  24  and  27  has  to  be  con-
idered  abnormal,  especially  when  the  patient  is  not  very  old
age  <  80  years),  has  a  high  educational  level  and  has  symp-
oms  involving  the  memory  or  other  cognitive  functions.  An
bnormal  MMSE  score  indicates  cognitive  dysfunction  not
ecessarily  related  to  dementia.  This  is  why  an  abnormal
core  is  not  enough  to  conﬁrm  the  diagnosis  and  further  spe-
ialized  assessment  is  required.  More  rapid  tests  can  be  used
o  detect  cognitive  disorders  in  the  elderly,  such  as  the  Mem-
ry  Impairment  Screen  (MIS)  (Appendix  2),  CODEX  (Appendix
),  the  ﬁve-word  test,  the  clock  test,  etc.  Whatever  the
est  used,  abnormal  results  indicate  a  strong  probability  of
310  O.  Hanon  et  al.
Table  3  Geriatric  assessment  of  elderly  people  with  atrial  ﬁbrillation.
Dimension  Brief  screening  More  complete
assessment
Interpretation
Cognitive
function
MIS  (score  0—8)  MMSE  (score  0—30) Cognitive  disorders  if:  immediate  and/or
delayed  MIS  ≤  6;  or  ﬁve  words  <  9;  or  clock
test  abnormal;  or  abnormal  CODEX;  or
MMSE  ≤  27  (or  ≤  24  if  low  educational  level)
Clock  test  (normal/abnormal) Neuropsychological
testsCODEX  (normal/abnormal)
Dependency Four-item  IADL  (score  0—4) IADL  (score  0—14) Possible  dependency  if  four-item  IADL  <  4
Dependency  if  IADL  <  14
ADL  (score  0—6)  Severe  dependency  if  ADL  <  6
Depressive
symptoms
Mini  GDS  (score  0—4)  GDS  (score  0—30) Possible  depression  if  Mini  GDS  ≥  1
Probable  depression  if  GDS  ≥  15
Nutritional
status
Weight  variation MNA  (score  0—30) Malnutrition  if:  weight  loss  >  5%  in  1
month;  or  >  10%  in  6  months;  or  MNA  <  17;
or  serum  albumin  <  35  g/L
Serum  albumin
Risk  of  fall  One-leg  balance  test  TUG  test  High  risk  of  fall  if;  one-leg  balance  test  <  5  s;
and/or  TUG  >  20  s
Living  condition  Interview  with  patient  and
family
Social  isolation,  safety  of  the  treatment  and
follow-up  organization
ADL: Activities of Daily Living; CODEX: Cognitive Disorders Examination; GDS: Geriatric Depression Scale; IADL: Instrumental Activities
of Daily Living; MIS: Memory Impairment Screen; MMSE: Mini Mental State Examination; MNA: Mini Nutritional Assessment; TUG: Timed
Up and Go.
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Aognitive  disorders  and  indicate  the  need  for  a  specialized
ssessment.
ssessment of  dependency
ependency  is  deﬁned  as  the  need  for  support  by  a  third  per-
on  to  carry  out  activities  of  daily  living.  Autonomy  can  be
valuated  by  scales  that  assess  activities  of  daily  life  (Instru-
ental  Activities  of  Daily  Living  [60]  and  Activities  of  Daily
iving  (Appendix  4))  through  questioning  the  patient  and
heir  relatives.  The  short  form  of  the  Instrumental  Activi-
ies  of  Daily  Living  scale  (Appendix  5)  includes  the  following
our  items:  ability  to  use  telephone,  mode  of  transporta-
ion,  responsibility  for  own  medication  and  ability  to  handle
nances.  The  Activities  of  Daily  Living  scale  gives  informa-
ion  about  personal  hygiene  and  grooming,  dressing,  ability
o  go  to  the  toilet,  transferring,  continence  and  feeding
utonomy.  A  subject  is  considered  dependent  when  they
eed  personal  assistance  in  performing  a  given  activity.
ait disorders and risk of falls
he  risk  of  fall  related  to  postural  instability  plays  a  role  in
he  therapeutic  choice  (cf.  paragraph  on  falls  and  vitamin  K
ntagonists).  The  assessment  of  the  risk  of  fall  is  based  on
aking  a  history  (history  of  falls),  physical  examination  (gen-
ral  health  status,  neuromuscular  status,  joint  status,  vision
nd  neurological  and  cardiovascular  examination,  searching
or  orthostatic  hypotension  in  particular)  and  simple  tests
uch  as  the  one-leg  balance  test,  which  evaluates  the  abil-
ty  to  stand  unaided  for  5  seconds  on  one  leg,  and  the  Timed
p  and  Go  test,  which  measures  the  time  taken  to  stand  up
rom  a  standard  armchair,  walk  3  m,  turn  around,  walk  back
a
t
i
do  the  chair  and  sit  down  again.  A  time  more  than  20  seconds
ndicates  a  risk  of  falls.
ssessment of nutritional status
 systematic  measurement  of  weight  should  be  taken  in
lderly  subjects.  Malnutrition  is  deﬁned  as  weight  loss  of
bove  5%  in  1  month  or  above  10%  in  6  months;  it  indicates
he  presence  of  an  at-risk  situation.  Weight  interpretation
hould  consider  clinical  and  biological  elements  of  ﬂuid
etention  or  dehydration.  The  nutritional  assessment  can
lso  be  done  by  means  of  a  validated  scale  (Mini  Nutritional
ssessment)  and  serum  albumin.  A  Mini  Nutritional  Assess-
ent  score  less  than  17  or  a  serum  albumin  concentration
ess  than  35  g/L  indicates  malnutrition.
ssessment of mood disorders
he  Mini  Geriatric  Depression  Scale  is  a  rapid  four-question
creening  test  (Appendix  6).  In  case  of  abnormal  result,
he  complete  Geriatric  Depression  Scale  allows  collection
f  depressive  symptoms.  A  score  of  15/30  or  more  indicates
ossible  depression  and  a  score  greater  than  22/30  indicates
ossible  major  depression.  Depression  in  the  elderly  subject
s  associated  with  worse  cardiovascular  prognosis  and  lower
ompliance  with  treatment  [61].
ssessment of living conditions
ssessment  of  living  conditions  aims  to  determine  compli-
nce  with  prescribed  treatment.  If  patients  cannot  manage
heir  own  treatments,  it  is  important  to  organize  the  admin-
stration  of  medication  (purchase,  preparation,  use  of  a  pill
ispenser,  involvement  of  family  members,  nurse  or  social
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age  of  75  years,  the  dabigatran  group  still  showed  a  reduced
cerebral  haemorrhage  risk  [72].
The  use  of  dabigatran  in  the  elderly  requires  some  pre-Atrial  ﬁbrillation  in  the  elderly  
worker).  It  is  also  important  to  determine  the  state  of  iso-
lation  of  the  patients  and  to  consider  the  involvement  of
caregivers,  as  well  access  to  various  care  services.  Educat-
ing  and  informing  patients  and  families  about  the  disease  is
required  in  order  to  ensure  medication  administration  and
an  understanding  of  the  complications.
Treatment
The  objectives  of  AF  treatment  in  the  elderly  are  to:  prevent
AF  complications,  particularly  stroke  and  thromboembolism;
reduce  mortality;  reduce  the  number  of  hospitalizations;
reduce  symptoms;  and  improve  quality  of  life.
Preventing  AF  complications  relies  mainly  on  anticoag-
ulant  therapy.  Management  also  involves  the  treatment  of
underlying  cardiomyopathy  and  heart  rate  control.
Stroke prevention: antithrombotic therapy
Antithrombotics  are  used  in  the  prevention  of  systemic
embolisms.
Stroke prevention: the place of oral
anticoagulants
Vitamin  K  antagonists  (VKAs)
The  beneﬁts  of  VKAs  have  been  largely  shown  in  patients
with  AF  and  appear  to  be  even  more  important  among
elderly  people  [62].  VKAs  reduce  the  risk  of  stroke  by  64%
compared  with  placebo  and  by  39%  compared  with  aspirin,
whereas  aspirin  only  reduces  the  risk  by  22%  [63]  compared
with  placebo.  A  randomized  trial  (the  BAFTA  study)  [38]  was
speciﬁcally  conducted  in  subjects  aged  75  years  or  more  with
AF.  The  results  conﬁrmed  the  beneﬁt  of  VKAs,  with  a  signiﬁ-
cant  reduction  of  52%  (relative  risk  [RR]  0.48,  95%  conﬁdence
interval  [CI]  0.28—0.80;  P  =  0.003)  in  the  embolic  risk  (cere-
bral/systemic)  for  warfarin  compared  with  aspirin.  Another
randomized  study  that  included  very  old  patients  (>  80  years)
[64]  showed  a  reduction  in  cardiovascular  events  for  VKAs
compared  with  aspirin  after  a  1-year  follow-up  period  (6%
vs  13%;  P  <  0.01).  These  beneﬁts  were  also  conﬁrmed  in  an
observational  study  (ATRIA)  [8].  Concerning  the  target  INR,
values  must  range  between  2.0  and  3.0.  Prevention  is  insufﬁ-
cient  with  an  INR  level  less  than  2.0,  and  an  INR  greater  than
3.0  does  not  give  any  additional  beneﬁts,  while  signiﬁcantly
increasing  the  risk  of  bleeding.
Assessment  of  embolic  risk  and  the  indication  for  vita-
min K  antagonists  in  the  elderly
The  embolic  risk  of  stroke  is  evaluated  with  the  CHADS2
score  (Table  1),  which  includes  age  of  75  years  or  more.
In  2006,  it  was  recommended  to  use  VKAs  when  the  CHADS2
score  is  greater  than  or  equal  to  2  [1],  as  is  the  case  with
most  patients  aged  75  years  or  more.  With  a  CHADS2 of  1,  the
choice  between  VKA  and  aspirin  was  to  be  made  according
to  patient  context  and  preferences.
In  2010,  the  ESC  proposed  a  new  score  (the  CHA2DS2-VASc
score;  Table  1)  [44].  This  score  gives  greater  importance  to
the  age  factor  when  determining  the  indications  for  anti-
coagulant  therapy  (Table  1).  On  the  basis  of  this  score,
anticoagulant  therapy  is  recommended  in  all  patients  aged
c
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n
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5  years  or  more  with  AF,  after  considering  the  bleeding  risk
43,65].
odalities  of  vitamin  K  antagonist  prescription
n  the  elderly,  the  use  of  warfarin  is  recommended  because
t  has  a  higher  level  of  evidence  and  is  easy  to  titrate.  A
alidated  scheme  for  warfarin  initiation  in  elderly  people  is
hown  in  Table  4 [66,67].
Once  the  patient  is  stable,  an  INR  is  performed  every
5—21  days.  INR  monitoring  should  also  to  be  done  in  case
f  an  acute  event  and  within  48—72  hours  after  discontinua-
ion  or  introduction  of  a new  drug,  especially  antibiotics  or
ntimycotics.
Other  than  in  cases  of  a  very  labile  INR,  it  is  not  rec-
mmended  to  follow  a  speciﬁc  diet  by  avoiding  foods  rich  in
itamin  K.  The  education  of  patients  and/or  their  caregivers
s  necessary.  Every  patient  should  use  a  treatment  diary  to
ecord  their  INR  results.  The  French  version  is  available  at
he  French  Federation  of  Cardiology:  infos@fedecardio.com.
ovel  oral  anticoagulants  (NOACS)
ew  prospects  have  been  opened  up  with  the  NOACs,
hich  do  not  require  monitoring  of  coagulation  factors  or
latelets:  the  oral  direct  thrombin  inhibitor  dabigatran  [68]
nd  the  oral  factor  Xa  inhibitors  rivaroxaban  [69],  apixaban
70]  and  edoxaban  [71].  The  recent  ESC  update  [43]  proposes
hat  NOACs  be  considered  as  ﬁrst-line  treatment  because  of
heir  net  clinical  beneﬁt  versus  VKAs,  after  assessment  of
aemorrhagic  risk  and  renal  function  (calculation  of  creati-
ine  clearance  with  the  Cockcroft  formula).
ral  direct  thrombin  inhibitor  (dabigatran)
n  the  RE-LY  study,  which  included  18,113  patients  (mean
ge  of  71.5  years)  with  non-valvular  AF  and  at  least  one
dditional  embolic  risk  factor,  the  incidence  of  stroke  or
ystemic  embolism  was  signiﬁcantly  lower  with  dabigatran
50  mg  twice  a  day  than  with  warfarin  (34%  relative  risk
eduction)  [68].  Similar  incidences  were  found  in  the  dabi-
atran  110  mg  twice  a  day  group  and  the  warfarin  group.
ompared  with  the  warfarin  group,  the  risk  of  major  bleed-
ng  was  statistically  lower  with  dabigatran  110  mg  twice  a
ay  (20%  relative  risk  reduction)  but  was  not  different  with
abigatran  150  mg  twice  a  day.  The  risk  of  cerebral  haemorr-
age  was  signiﬁcantly  lower  with  both  doses  of  dabigatran
ompared  with  warfarin  (60%  reduction  risk  with  dabigatran
50  mg  twice  a  day  and  69%  reduction  risk  with  dabigatran
10  mg  twice  a  day).  In  the  subgroup  of  subjects  aged  75
ears  or  more  (n  =  7258),  the  reduction  of  thromboembolic
isk  remained  similar  to  that  observed  in  those  aged  less
han  75  years.  On  the  other  hand,  the  risk  of  major  bleeding
ncreased  with  age:  after  age  75  years,  it  was  higher  than
hat  for  VKAs  with  the  150  mg  twice  a  day  dose  and  simi-
ar  to  that  for  VKAs  with  110  mg  twice  a  day  dose.  After  theautions  because  it  is  mainly  eliminated  by  the  kidneys  (80%
enal  elimination).  Dabigatran  is  contraindicated  if  creati-
ine  clearance  calculated  according  to  Cockcroft  formula  is
ess  than  30  mL/min.
312  O.  Hanon  et  al.
Table  4  Initiation  of  warfarin  therapy  in  elderly  people.
Day  INR  in  the  morning  Daily  dose  of  warfarin
First  dose  =  day  0  No  measure  4  mg
Second  dose  =  day  1  No  measure  4  mg
Third  dose  =  day  2  No  measure  4  mg
Day  3  (the  day  after  the
third  dose)
< 1.3  5  mg
1.3  ≤  INR  <  1.5  4  mg
1.5  ≤  INR  <  1.7 3  mg
1.7  ≤  INR  <  1.9 2  mg
1.9  ≤  INR  <  2.5 1  mg
INR  ≥  2.5  Measure  INR  daily  and  omit  doses  until  INR  <  2.5  then  give  1  mg
Day  6  ±  1 INR  ≤  1.6  1  mg  increase
1.6  <  INR  ≤  2.5  Maintain  the  day  3  dose
2.5  <  INR  ≤  3.5 If dose  ≥  2  mg:  1  mg  reduction
If  dose  =  1  mg:  maintain  same  dose  (1  mg)
INR  >  3.5  Manage  according  to  overdose  guidelines  (HAS  2008a)
Adapted from Siguret et al. and Gouin-Thibault et al. [66,67].
HAS: Haute Autorité de Santé; INR: international normalized ratio. Further control 48—72 hours after IRN stability has been reached.
a http://www.has-sante.fr/portail/upload/docs/application/pdf/2008-09/surdosage en avk situations a risque et accidents
hemorragiques - synthese des recommandations v2.pdf.
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mIn  summary,  a  lower  dose  of  dabigatran  (110  mg  twice  a
ay)  is  recommended  after  the  age  of  80  years  or  after  the
ge  of  75  years  in  case  of  high  haemorrhagic  risk:  creatinine
learance  30—50  mL/min  (Cockcroft  formula)  or  low  weight
<  50  kg)  or  HAS-BLED  score  greater  than  or  equal  to  3.
ral  direct  factor  Xa  inhibitors
ther  antithrombotic  drugs  targeting  factor  Xa  have  been
eveloped  (rivaroxaban,  apixaban,  and  edoxaban);  their
enal  elimination  is  about  30%.
Rivaroxaban.  The  double-blind  ROCKET  AF  study  [69]
as  designed  as  a  non-inferiority  trial  comparing  rivaroxa-
an  with  warfarin  for  the  prevention  of  stroke  or  systemic
mbolism  in  non-valvular  AF  patients.  Rivaroxaban  was  used
n  14,264  patients  with  a  median  age  of  73  years,  at  a  dose  of
0  mg  once  daily  or  15  mg  once  daily  for  patients  with  cre-
tinine  clearance  30—50  mL/min.  Patients  included  in  this
tudy  had  higher  CHADS2 scores  compared  with  those  in  the
E-LY  study.  Rivaroxaban  was  non-inferior  to  warfarin  for  the
revention  of  ischaemic  and  haemorrhagic  stroke  and  sys-
emic  embolism.  Moreover  the  risk  of  major  and  non  major
linically  relevant  bleeding  was  similar  between  Rivarox-
ban  and  warfarin.  A  signiﬁcant  reduction  in  intracranial
aemorrhage  was  observed  compared  with  warfarin  (reduc-
ion  of  33%).  The  analysis  of  subgroups  of  patients  aged  75
ears  or  more  (n  =  6164),  as  well  as  those  with  moderate
enal  failure  (clearance  30—49  mL/min;  n  =  2950),  showed
esults  similar  to  those  in  the  general  population,  with  non-
nferiority  of  rivaroxaban  compared  with  warfarin  for  the
revention  of  thromboembolic  and  haemorrhagic  strokes
73].  In  summary,  the  dose  of  15  mg  once  a  day  is  recom-
ended  in  elderly  patients  with  a  creatinine  clearance  of
0—50  mL/min  (Cockcroft  formula).  Rivaroxaban  is  not  rec-
mmended  in  the  elderly  if  creatinine  clearance  calculated
ccording  to  the  Cockcroft  formula  is  less  than  30  mL/min.
Apixaban.  Apixaban,  used  in  the  AVERROES  trial  at
he  dose  of  5  mg  twice  a  day,  was  compared  using  a
d
t
e
oouble-blind  design  with  aspirin  in  5599  patients  with  a
ean  age  of  70  years,  who  were  unsuitable  for  VKA  ther-
py  [74]. The  AVERROES  trial  was  stopped  early  because  of
he  beneﬁts  of  apixaban  compared  with  aspirin  (55%  reduc-
ion  of  stroke  or  systemic  embolism;  P  <  0.001).  Apixaban
5  mg  twice  a  day)  has  also  been  compared  with  warfarin  in
he  double-blind  ARISTOTLE  trial,  conducted  in  18  201  AF
atients,  median  age  of  70  years  [70]. The  results  indicated
uperiority  of  apixaban  compared  with  warfarin,  character-
zed  by  a  signiﬁcant  reduction  in  thromboembolic  events
21%),  major  bleedings  (31%)  and  total  mortality  (11%).  As
n  the  RE-LY  and  ROCKET  studies,  a  signiﬁcant  reduction
n  intracranial  haemorrhage  was  observed  (58%  reduction).
imilarly,  the  analysis  of  subgroups  of  patients  aged  above
5  years  (n  = 5678)  found  a  signiﬁcant  beneﬁt  for  apixaban  in
he  reduction  of  thromboembolic  events  and  major  bleed-
ngs.  Apixaban  was  used  at  a  dose  of  5  mg  twice  a  day  or
.5  mg  twice  a  day  in  patients  with  at  least  two  of  the  fol-
owing  criteria:  aged  above  80  years;  creatinine  greater  than
33  mol/L;  weight  less  than  60  kg.  Apixaban  is  not  rec-
mmended  in  the  elderly  if  creatinine  clearance  calculated
ccording  to  the  Cockcroft  formula  is  less  than  30  mL/min.
Other  oral  direct  factor  Xa  inhibitors  have  been  devel-
ped,  such  as  edoxaban,  which  is  currently  being  studied
n  the  ongoing  ENGAGES  AF  TIMI  48  trial,  which  is  in  the
ollow-up  phase.
A  meta-analysis  [75]  of  the  RE-LY,  ROCKET  and  ARISTOTLE
rials,  which  included  44,563  subjects,  found  better  efﬁcacy
ith  the  NOACs  compared  with  warfarin  for  stroke  preven-
ion  (RR  0.78,  95%  CI  0.67—0.92),  associated  with  a  lower  risk
f  intracranial  haemorrhage  (RR  =  0.49,  95%  CI  0.36—0.66).
In  summary,  NOACs  are  promising  treatments  for  the
anagement  of  non-valvular  AF  in  elderly  people,  especially
ue  to  a  lower  risk  of  intracerebral  haemorrhage.  However,
heir  prescription  should  take  into  account  some  important
lements,  such  as  their  renal  elimination  and  the  absence
f  monitoring;  they  are  contraindicated  in  case  of  severe
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acceptable  risk—beneﬁt  ratio  reported  by  many  randomized
trials.  This  risk  perception  is  related  to  the  fact  that  elderlyAtrial  ﬁbrillation  in  the  elderly  
renal  failure  deﬁned  by  a  creatinine  clearance  less  than
30  mL/min.  The  Cockcroft  formula  has  to  be  systematically
used  for  renal  function  assessment  because  this  formula  was
used  in  all  the  trials  that  evaluated  these  new  drugs.  Adher-
ence  to  treatment  is  important  due  to  the  short  elimination
half-life  of  these  molecules  compared  with  VKAs,  as  well  as
the  absence  of  therapeutic  monitoring,  so  their  use  requires
an  assessment  of  cognitive  function.  Lastly,  although  the
RE-LY,  ROCKET  and  ARISTOTLE  trials  included  about  19,000
subjects  aged  above  75  years,  a  relatively  small  number  of
frail  patients  aged  above  80  years  were  included  in  these
trials.  Studies  including  frail  patients  (age  >  80  years,  renal
failure)  are  thus  necessary  to  evaluate  tolerance  in  ‘‘real
life’’.  In  the  future,  the  reversal  of  the  anticoagulant  effect
and  the  development  of  speciﬁc  biological  tests  in  case  of
acute  severe  bleeding  are  important  challenges  in  elderly
patients.
Antiplatelet agents
In  the  latest  update  in  2012,  the  ESC  guidelines  for  the
management  of  AF  [43]  no  longer  recommend  aspirin  unless
patients  refuse  the  use  of  any  oral  anticoagulant  (VKAs  or
NOACs).  Indeed,  the  evidence  for  stroke  prevention  with
aspirin  in  AF  is  weak  and  the  risk  of  major  bleeding  or
intracranial  haemorrhage  with  aspirin  is  not  signiﬁcantly
different  to  that  of  oral  anticoagulants,  especially  in  the
elderly.  Indeed,  in  the  ATRIA  cohort,  the  annual  incidence
of  intracerebral  haemorrhage  after  the  age  of  80  years  was
similar  with  VKAs  (0.70%)  and  aspirin  (0.69%)  [8].  Moreover,
in  BAFTA  study,  the  annual  incidence  of  major  bleeding  in
patients  aged  above  85  years  was  2.9%  with  VKAs  and  3.7%
with  aspirin  [38].
Clopidogrel  monotherapy  is  not  indicated  in  AF  in
the  absence  of  documented  study.  The  combination  of
aspirin  75  mg/day  with  clopidogrel  75  mg/day  was  supe-
rior  to  aspirin  alone  for  stroke  prevention  but  with  a
higher  haemorrhagic  risk  [76].  Moreover,  no  positive  effect
on  thromboembolic  risk  was  observed  in  the  subgroup  of
patients  aged  above  75  years.
In  the  elderly,  the  association  of  an  anticoagulant  with  an
antiplatelet  agent  raises  the  bleeding  risk,  so  the  use  of  this
combination  is  restricted  to  particular  cases  (acute  coronary
syndrome,  stents;  cf.  paragraph  on  coronary  patients).  The
combination  of  anticoagulant  plus  aspirin  plus  clopidogrel,
if  unavoidable,  should  be  used  for  as  short  a  time  as  possible
[77].
In  the  patient  with  coronary  artery  disease
The  selection  of  antithrombotic  therapy  depends  on  three
main  factors:  the  clinical  context  (acute  coronary  syndrome
or  stable  patient);  the  revascularization  by  angioplasty  (in
particular  the  type  of  stent);  and  the  bleeding  risk.  In  elderly
patients  aged  above  75  years,  who  are  generally  consid-
ered  to  be  at  high  bleeding  risk,  the  use  of  drug-eluting
stents  should  be  avoided  and  triple  therapy  (combination  of
an  oral  anticoagulant  with  two  antiplatelet  agents)  should
be  used  for  as  short  a  time  as  possible.  Table  5,  based  on
expert  assessment  and  not  on  published  randomized  stud-
ies  assessing  beneﬁt-risk  balance,  shows  the  main  clinical
situations.
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trial  ﬁbrillation  patient  aged  75  years  or  more  with
table coronary  artery  disease
n  the  absence  of  recent  revascularization  by  angioplasty,
ong-term  treatment  with  an  oral  anticoagulant  (VKA  or
robably  NOAC)  without  an  antiplatelet  drug  is  sufﬁcient.
In  case  of  recent  revascularization  by  stent,  triple  ther-
py  (aspirin  plus  clopidogrel  plus  oral  anticoagulant)  is
ecommended  for  2—4  weeks,  then  the  combination  of  an
ral  anticoagulant  with  only  one  antiplatelet  drug  is  nec-
ssary  for  1—12  months  after  stent  placement  (according  to
leeding  risk).  Beyond  that,  oral  anticoagulant  monotherapy
s  sufﬁcient.
trial  ﬁbrillation  patient  aged  75  years  or  more  fol-
owing an  acute  coronary  syndrome
n  the  absence  of  revascularization  procedure,  the  duration
f  use  of  triple  therapy  (aspirin  plus  clopidogrel  plus  oral
nticoagulant)  should  be  kept  as  short  as  possible  (maximum
 month  [2—4  weeks]).  It  is  preferable  to  continue  the  com-
ination  of  an  oral  anticoagulant  plus  one  antiplatelet  agent
or  12  months.  The  duration  varies  according  to  the  bleeding
isk  (1  month  minimum).  Beyond  that,  an  oral  anticoagulant
s  monotherapy  is  sufﬁcient.
In  case  of  revascularization  by  angioplasty,  initial  triple
herapy  (oral  anticoagulant  plus  aspirin  plus  clopidogrel)  is
ecommended  for  a  period  of  4 weeks  to  6  months.  How-
ver,  because  the  bleeding  risk  is  increased  after  the  age
f  75  years,  the  duration  of  the  triple  therapy  is  usually
ot  longer  than  4  weeks.  After  triple  therapy,  combina-
ion  therapy  (oral  anticoagulant  plus  one  antiplatelet  agent)
s  recommended  for  a  maximum  of  12  months.  Beyond
hat,  oral  anticoagulant  monotherapy  is  sufﬁcient.  The  con-
inuation  of  the  combination  therapy  beyond  this  period,
owever,  varies  according  to  the  bleeding  and  thrombotic
isks.
The  use  of  a  bare-metal  stent  is  preferred  due  to  the
act  that  triple  therapy  in  this  case  is  limited  to  4  weeks.
xceptionally,  drug-eluting  stents  can  be  used  in  complex
ituations  (intrastent  restenosis)  and  require  much  longer
riple  therapy  (3—6  months)  or,  if  needed,  dual  antiplatelet
herapy  with  temporary  oral  anticoagulant  discontinuation.
he  WOEST  study  (not  yet  published),  which  was  presented
o  the  ESC  Congress  in  2012,  showed  that  in  subjects  with
ral  anticoagulation  and  coronary  stenting,  treatment  with
lopidogrel  plus  VKA  was  signiﬁcantly  less  associated  with
aemorrhagic  events  than  clopidogrel  plus  aspirin  plus  VKA,
ith  no  more  stent  thromboses.
leeding risk related to vitamin K  antagonists
KAs  are  underused  in  elderly  people  with  AF  [78,79]
ho  have  no  contraindication  for  such  medications.  The
ain  reason  is  the  fear  of  bleeding  among  the  majority
f  physicians.  This  risk  is  often  overestimated  despite  anatients  enrolled  in  these  trials  are  not  representative  of
ll  patients  in  whom  VKAs  are  indicated,  particularly  very
ld  people  with  multiple  co-morbidities  and/or  cognitive
isorders.
314  O.  Hanon  et  al.
Table  5  Antithrombotic  treatment  in  subjects  aged  75  years  or  above  with  coronary  heart  disease  and  atrial  ﬁbrillation.
Clinical  situation  Treatment
Coronary  patient  without
stent
Stable  coronary  artery  disease  Long-term  OACa therapy
Unstable  coronary  artery Triple  therapy  2—4  weeks
Then  OAC  +  aspirin  or  clopidogrel  up  to  12  monthsa
Then  OAC  alone
Coronary  patient  with  stentb Stable Triple  therapy  2—4  weeks  if  bare-metal  stent
Then  OAC  +  aspirin  or  clopidogrel  up  to  12  months
Then  OAC  alone
Unstable Triple  therapy  4 weeks  if  bare-metal  stent
Then  OAC  +  aspirin  or  clopidogrel  up  to  12  monthsa
Then  OAC  alonec
INR: international normalized ratio; OAC: oral anticoagulant; VKA: vitamin K antagonist. OAC: VKA or probably novel oral anticoagulant.
VKA with double or triple therapy: INR between 2 and 2.5. VKA used alone: target INR between 2 and 3.
a 1—12-month duration according to stability of coronary heart disease, thrombotic risk of stent and bleeding risk of subject.
b The use of a bare-metal stent is preferred for subjects aged ≥ 75 years.
c The continuation of double therapy beyond 12 months can be discussed depending on the bleeding and thrombotic risks.
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an  INR  that  exceeds  the  therapeutic  range.  It  is  preferable,
therefore,  to  undertake  more  frequent  INR  monitoring  com-
pared  with  that  in  younger  adults  (every  15  or  21  days  once
the  treatment  is  adjusted).
Vascular  fragility  or  potentially  unknown  haemorrhagic
lesions  may  be  present.
There  may  be  co-prescription  of  medications  that  lead
to  INR  modiﬁcations  (some  antibiotic  and  antifungal  drugs,
amiodarone,  statins,  ﬁbrates,  paracetamol,  tramadol,  thy-
roid  hormones,  serotonin  reuptake  inhibitors)  or  drugs  that
raise  the  bleeding  risk  without  modifying  INR  (heparin,
Table  6  HEMORR2HAGES  scores  for  bleeding  risk  assess-
ment  in  patients  receiving  vitamin  K  antagonists.
Item  Score
Hepatic  or  renal  disease  1
Ethanol  abuse  1
Malignancy  1
Older  (age  >  75  years)  1
Reduced  platelet  count  or  function  1
Rebleeding  risk  2
Hypertension  uncontrolled  1
Anemia  1
Genetic  factors  (CYP  2C9) 1
Excessive  fall  risk  or  neuropsychiatric  disease  1
Stroke  1
HEMORR2HAGES
total  score
Bleeds  per  100
patient-years
0  1.9
1  2.5
2  5.3
3  8.4
4  10.4afety  of  vitamin  K  antagonist  treatment  in  the
lderly
he  incidence  of  major  bleedings  related  to  VKAs  varies
rom  1%  to  13%  per  year  [80—84]  and  clearly  increases  in
he  frail  elderly  and  in  very  old  people  [82,85,86].  The  risk
f  major  bleeding  is  higher  in  the  ﬁrst  months  following
reatment  initiation  [82],  then  decreases  during  long-term
reatment  but  does  not  completely  disappear.  In  France,
KA-related  bleeding  events  are  mainly  due  to  serious  iatro-
enic  accidents  requiring  emergency  hospitalization  [87].
 better  knowledge  of  VKA-related  bleeding  risk  factors
88—90]  enables  detection  of  patients  in  whom  the  risk  of
leeding  outweighs  the  beneﬁt  of  VKAs.  On  the  other  hand,
 more  objective  evaluation  of  the  risk  can  lead  to  VKA  pre-
cription  in  patients  untreated  because  of  an  excessive  fear
f  bleeding  risk.
ssessment  of  bleeding  risk  in  patients  treated
ith vitamin  K  antagonists
everal  scores  are  available  for  assessing  the  bleeding  risk
n  patients  who  are  being  or  will  be  treated  with  VKAs
91—95].  These  scores  are  based  on  the  identiﬁcation  of  cer-
ain  factors  known  to  increase  the  bleeding  risk.  The  most
sed  scores  are  HEMORR2HAGES  [92]  and  HAS-BLED  [94].
he  HEMORR2HAGES  score  was  studied  in  elderly  patients
ith  a  mean  age  of  80  years,  so  it  is  the  most  suitable
core  to  assess  bleeding  risk  in  elderly  patients  receiving
KAs  (Table  6).  The  HAS-BLED  score,  recently  proposed  by
he  ESC,  is  simple  to  carry  out  but  was  based  on  a  popula-
ion  with  a  mean  age  of  66  years  and  includes  fewer  items
oncerning  elderly  co-morbidities,  such  as  falls  or  cognitive
isorders  (Table  7).
The  increase  in  VKA-related  bleeding  risk  with  age  is
till  not  well  understood.  The  bleeding  risk  increases  with
ge  independent  of  the  overdose  risk.  Potential  reasons  are
isted  below.
The  modiﬁcations  to  VKA  pharmacodynamics  that  occur
uring  the  process  of  ageing  explain  the  difﬁculty  in  obtain-
ng  long-term  INR  stability  in  this  population,  with  a risk  of
≥  5  12.5
Adapted from Gage et al. [92].
Atrial  ﬁbrillation  in  the  elderly  
Table  7  HAS-BLED  score  for  bleeding  risk  assessment  in
patients  receiving  vitamin  K  antagonists.
Item  Points
Hypertension  (SBP  >  160  mmHg)  1
Abnormal  renala or  liverb function
(1  point  each)
1  or  2
Stroke  1
Bleeding  1
Labile  INR 1
Elderly  (age  >  65  years) 1
Drugs  with  bleeding  riskc or
alcohol  (1  point  each)
1  or  2
Adapted from Pisters et al. [94].
INR: international normalized ratio; SBP: systolic blood pressure.
a Serum creatinine ≥ 200 mol/L.
b Chronic liver diseases (cirrhosis) or abnormal liver blood tests
(bilirubin 2 × normal limits; aspartate aminotransferase/alanine
aminotransferase 3 × normal limits; etc.)
c Antiplatelet drugs, non-steroidal anti-inﬂammatory drugs.
o
c
A
w
T
N
H
l
c
o
d
t
S
a
o
b
e
A
T
T
d
t
i
c
t
s
v
m
p
i
b
p
a
r
S
t
h
h
o
i
e
o
s
r
[
d
u
s
n
a
shown  that  rate  control  is  a  cost-effective  strategy  com-antiplatelets,  non-steroidal  anti-inﬂammatory  drugs).  When
a  new  medication  is  started,  it  is  essential  to  monitor  INR
for  48—72  hours  after  drug  initiation.
The  incidence  of  recurrent  falls  increases  with  age  and
these  are  often  considered  to  be  a  bleeding  risk  factor.  In
fact,  few  studies  have  documented  and  quantiﬁed  this  risk.
In  a  retrospective  study  [96],  the  risk—beneﬁt  ratio  was
in  favour  of  VKA  prescription  despite  a  twofold  increased
intracranial  haemorrhage  risk  in  recurrent  fallers.  Another
observational  study,  conducted  in  4093  patients  aged  above
80  years  treated  with  VKAs,  showed  a  threefold  increased
risk  of  major  bleeding  in  fallers  [97].  In  case  of  recurrent
falls  without  modiﬁable  underlying  cause,  VKA  prescription
should  be  avoided,  especially  if  life  expectancy  is  reduced.
In  addition,  geriatric  assessment  and  preventive  manage-
ment  are  needed  to  avoid  the  occurrence  of  new  falls.
Cognitive  disorders  are  associated  with  poorer  INR  con-
trol  and  therefore  with  an  increased  bleeding  risk.  Memory
disorders  can  result  in  errors  in  medication  intake,  e.g.  the
patient  forgets  to  take  their  medication  or  takes  it  twice.
These  mistakes  must  be  prevented.  To  do  so,  cognitive  dis-
orders  must  be  sought  when  an  anticoagulant  treatment
is  being  considered  (see  geriatric  assessment).  Anticoagu-
lant  therapy  in  cognitively  impaired  patients  requires  the
involvement  of  the  caregiver  for  the  administration  of  med-
ications  as  well  as  the  therapeutic  education  of  patients’
relatives.
Protein-energy  malnutrition  is  frequent  in  the  elderly.  In
case  of  sudden-onset  malnutrition,  particularly  in  the  set-
ting  of  inﬂammation,  serum  albumin  level  can  fall  rapidly.
With  VKAs  being  strongly  bound  to  serum  albumin,  the  risk
of  a  VKA  overdose  is  high  and  so  INR  monitoring  and  dose
adjustment  are  necessary.
Renal  insufﬁciency  is  frequent  in  the  elderly  and  raises
the  bleeding  risk.  In  this  situation,  a  careful  INR  monitoring
is  particularly  needed.
Elderly  subjects  often  combine  major  identiﬁed  bleeding
risk  factors  [98],  especially  impaired  renal  function  and  use
p
h
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f  antiplatelet  drugs,  explaining,  at  least  partly,  their  sus-
eptibility  to  haemorrhagic  complications  with  VKA  therapy.
ssessment  of  bleeding  risk  in  patients  treated
ith novel  oral  anticoagulants
here  are  currently  no  speciﬁc  bleeding  risk  scores  for
OACs.  The  usual  risk  factors  for  bleeding  (HAS-BLED  or
EMORR2HAGES  scores),  especially  age  above  75  years,
ow  weight,  creatinine  clearance  30—50  mL/min  and  asso-
iated  treatment  with  antiplatelet  or  drugs  inhibiting  P-Gp
r  CY3A4  inhibitors/inducers  (verapamil,  azole  antifungal
rugs,  rifampicin,  etc.),  can  be  considered  as  risk  fac-
ors  for  NOACs  while  awaiting  results  from  speciﬁc  studies.
evere  renal  insufﬁciency  (creatinine  clearance  <  30  mL/min
ccording  to  the  Cockcroft  formula)  contraindicates  the  use
f  NOACs.
In  elderly  patients  taking  NOACs,  renal  function  should
e  assessed  three  times  each  year  or  in  the  case  of  an  acute
vent  (e.g.  dehydration,  fever).
ntiarrhythmic drugs
herapeutic  strategies
he  therapeutic  strategy  in  elderly  AF  patients  does  not
iffer  basically  from  that  applied  in  the  younger  popula-
ion.  The  main  discussion  about  pharmacological  treatment
s  focused  on  the  choice  between  rhythm-control  and  rate-
ontrol  strategies  [65,99,100].
The  rhythm-control  strategy  aims  to  restore  and  main-
ain  normal  sinus  rhythm.  The  objective  of  the  rate-control
trategy  is  to  control  the  ventricular  rate  by  avoiding  rapid
entricular  response  without  speciﬁc  therapy  for  restoring  or
aintaining  sinus  rhythm.  Each  strategy  is  mainly  based  on
harmacological  treatments;  however  non-pharmacological
nterventions  and  hybrid  therapeutic  procedures  can  also
e  used.  To  date,  few  data  are  available  concerning  non-
harmacological  interventions,  particularly  radiofrequency
blation  of  AF  in  elderly  patients  [65].
Many  prospective  and  randomized  trials  have  compared
hythm-  and  rate-control  strategies:  PIAF,  AFFIRM,  RACE,
TAT,  HOT  CAFE,  AF-CHF,  etc.  [65]  Patients  included  in  these
rials  had  a  mean  age  of  70  years,  60%  were  men,  75—80%
ad  persistent  AF  and  90%  were  asymptomatic.  Few  patients
ad  heart  failure,  except  in  the  AF-CHF  study.  The  results
f  these  trials  are  consistent  and  showed  no  difference
n  mortality  rate  between  patients  assigned  to  one  strat-
gy  or  the  other  [65]. Nevertheless,  a  prespeciﬁed  analysis
f  the  AFFIRM  study  among  patients  aged  above  65  years
howed  that  the  rate-control  strategy  was  superior  to  the
hythm-control  strategy  for  mortality  and  stroke  criteria
101].  Ancillary  studies  suggested  that  increased  stroke  inci-
ence  in  the  rhythm-control  group  is  probably  related  to  the
nderuse  of  oral  anticoagulants  [99,101].
Finally,  the  AFFIRM  study  focused  on  the  impact  of  both
trategies  on  symptoms  and  cost  effectiveness.  There  was
o  difference  between  both  strategies  for  quality  of  life
nd  the  6-minute  walk  test  [102]. On  the  contrary,  it  wasared  with  rhythm  control,  mainly  due  to  a  reduction  in
ospitalizations  [102].  The  RACE  II  study,  which  compared
 strict  rate  control  strategy  (resting  heart  rate  <  80  beats
316  O.  Hanon  et  al.
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pigure 4. Heart rate control according to underlying heart diseas
er  minute)  with  a  ‘‘lenient’’  rate  control  strategy  (heart
ate  <  110  beats  per  minute),  did  not  show  any  difference  in
 composite  primary  outcome  that  included  cardiovascular
ortality,  hospitalizations  for  heart  failure  and  stroke,  sys-
emic  embolism,  bleeding  and  life-threatening  arrhythmic
vents  [103].
In  summary,  in  elderly  patients,  the  rate  control  strategy
hould  be  used  preferentially  in  most  cases.  However,  the
hoice  of  the  ‘‘return  to  normal  sinus  rhythm’’  strategy  can
e  considered  in  case  of  severe  persistent  symptoms  and  in
he  absence  of  advanced  cardiomyopathy  or  contraindica-
ion  to  the  use  of  antiarrhythmic  drugs.
harmacological  treatment
ate  control
he  latest  ESC  guidelines  recommend  the  rate-control  strat-
gy  as  ﬁrst-line  therapy  for  elderly  patients,  especially  if
hey  are  paucisymptomatic  [65].
In  case  of  haemodynamic  intolerance  or  severe  symptoms
elated  to  a  rapid  ventricular  rate,  a  rate-control  therapy
an  be  carried  out  by  the  intravenous  route  (beta-blockers,
on-dihydropyridine  calcium  channel  antagonists,  digoxin).
n  case  of  acute  heart  failure,  digoxin  is  recommended  [65].
In  the  long-term  rate  control  strategy,  the  choice  of  the
rug  should  take  into  account  the  presence  of  associated
eart  diseases  (Fig.  4).  In  the  absence  of  heart  disease,
eta-blockers,  non-dihydropyridine  calcium  channel  antag-
nists  and  digoxin  can  be  used.  In  patients  with  heart  failure,
eta-blockers  and  digoxin  are  recommended.  In  patients
ith  COPD,  small  doses  of  cardioselective  beta-blockers  may
e  used,  as  well  as  non-dihydropyridine  calcium  channel
ntagonists.  In  acute  congestive  heart  failure,  beta-blockers
nd  non-dihydropyridine  calcium  channel  antagonists  (ver-
pamil  and  diltiazem)  are  contraindicated.  Amiodarone  is
lso  effective  at  rate  control  but  is  rarely  used  in  this  indi-
ation  due  to  its  extracardiac  side-effects  [99,100].  Lastly,
he  combination  of  drugs  causing  bradycardia  should  be  used
autiously  and  under  careful  monitoring.
M
R
MAs  a  general  rule,  in  the  absence  of  contraindication,  it
s  recommended  to  use  beta-blockers  as  ﬁrst-line  therapy
n  AF  elderly  patients,  especially  in  case  of  underlying  heart
ailure  and/or  coronary  artery  disease.  The  AFFIRM  substudy
howed  that  beta-blockers  are  the  most  effective  at  rate
ontrol  [104]. On  the  other  hand,  digoxin  is  found  to  be
n  independent  risk  factor  for  death  in  AF  patients  with-
ut  heart  failure  [105].  Thus,  the  use  of  digoxin  in  elderly
atients  is  complex  due  to  its  renal  elimination  and  the  need
or  careful  monitoring.
A  less  strict  rate  control  therapy  can  be  sufﬁcient  in
atients  without  severe  symptoms.  Strict  rate  control  will  be
eeded  in  case  of  disabling  symptoms  or  suspicion  of  rhyth-
ic  cardiomyopathy.  If  pharmacological  therapy  fails,  rate
ontrol  can  be  achieved  by  atrioventricular  node  ablation
ssociated  with  the  insertion  of  a  pacemaker  or  some-
imes  an  automated  implantable  deﬁbrillator.  In  case  of  left
entricular  dysfunction  and  heart  failure,  a  biventricular
acemaker  is  needed.
hythm  control:  cardioversion
ardioversion,  whether  electrical  or  pharmacological,  is  less
requently  used  in  elderly  patients  due  to  higher  preva-
ence  of  permanent  AF  and  the  difﬁculty  in  maintaining  sinus
hythm;  the  rate-control  strategy  is  therefore  preferred  in
his  population.  Moreover,  both  types  of  cardioversion  can
ave  serious  side-effects,  especially  in  the  elderly  popula-
ion.  Electrical  cardioversion  requires  general  anaesthesia
nd  pharmacological  cardioversion  requires  drugs  that  can
e  contraindicated  and/or  have  adverse  events,  particularly
n  case  of  left  ventricular  dysfunction  or  heart  failure.  Oral
miodarone  is  often  used  in  this  situation  in  elderly  patients
65,99,100].  Documented  anticoagulation  for  3  weeks  (or
F  <  48  hours)  is  recommended  before  both  electrical  and
harmacological  cardioversion  [65].aintenance  of  sinus  rhythm
hythm  control  is  difﬁcult  to  obtain  in  elderly  patients.
aintaining  sinus  rhythm  involves  pharmacological  therapy,
Atrial  ﬁbrillation  in  the  elderly  317
ease.
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as  in  the  younger  population,  and  must  follow  ESC  recom-
mendations  [65].  The  use  of  antiarrhythmic  drugs  in  the
elderly  is  limited  because  of  the  frequently  associated  heart
diseases  and  the  high  prevalence  of  renal  and  hepatic  con-
ditions  that  modify  the  pharmacokinetics  of  the  drug  used.
Few  data  are  available  concerning  the  use  of  antiarrhythmic
drugs  in  this  speciﬁc  population.
The  choice  of  the  antiarrhythmic  therapy  depends  on
the  underlying  heart  disease  (Fig.  5):  for  coronary  heart
disease,  sotalol,  amiodarone  and  dronedarone  are  recom-
mended  [65];  for  left  ventricular  hypertrophy,  amiodarone
and  dronedarone  are  advised  [65];  for  heart  failure  (current
or  prior)  or  left  ventricular  dysfunction,  only  amiodarone  is
recommended.
Class  I  antiarrhythmic  drugs  are  not  recommended  in
case  of  heart  disease,  so  their  use  is  very  limited  in  the
elderly.  Lastly,  it  is  difﬁcult  to  reach  the  effective  doses
of  sotalol  in  elderly  patients  because  of  poor  tolerance
and  risk  of  torsades  de  pointes  [65].  Dronedarone  has  been
shown  to  improve  cardiovascular  morbimortality  (ATHENA
study)  [106],  especially  in  patients  aged  above  75  years
with  paroxysmal  or  persistent  AF.  On  the  other  hand,  in
the  ANDROMEDA  study,  the  use  of  dronedarone  in  patients
with  heart  failure  was  associated  with  increased  mortal-
ity  [107],  and  in  the  PALLAS  study,  its  use  in  patients  with
permanent  AF  was  associated  with  increased  cardiovascular
events  [108].  Consequently,  dronedarone  is  contraindicated
in  these  two  situations:  permanent  AF  and  heart  failure.Tolerance  to  antiarrhythmic  drugs  and  patient  follow-
up
Antiarrhythmic  drugs  should  be  used  with  caution  in  elderly
patients  because  of  the  frequent  metabolic  abnormalities
N
S
Snd  because  of  a  higher  risk  of  drug  interactions  and
radycardia.  All  antiarrhythmic  drugs  require  regular
onitoring  of  ECGs,  serum  potassium  and  renal  function
in  particular  digoxin,  class  I  agents,  sotalol).  Amiodarone
equires  speciﬁc  monitoring  (thyroid-stimulating  hormone,
iver  transaminases,  chest  X-ray).  In  patients  treated
ith  dronedarone,  health  authorities  recommend  regular
onitoring  of  liver  transaminases  after  the  notiﬁcation  of
wo  serious  cases  of  drug-induced  hepatitis  in  January  2011.
ulmonary  (dyspnoea,  dry  cough,  crackles,  chest  X-ray)  and
enal  function  (creatinine  clearance)  monitoring  are  also
ecommended  for  dronedarone.
Non-pharmacological  interventions  are  limited  in  elderly
atients,  particularly  AF  ablation.  AF  is  often  permanent,
eeding  complex  procedures  other  than  pulmonary  vein  iso-
ation,  which  is  less  successful  in  the  treatment  of  AF  in
he  elderly.  This  procedure  is  carried  out  rarely  in  elderly
atients  when  atrioventricular  node  ablation  is  contraindi-
ated  [65].
In  conclusion,  a  rate-control  strategy  is  the  treatment  of
hoice  for  AF  in  almost  all  elderly  patients.
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ppendix 1. Mini Mental State
xamination (MMSE) [59].
rientation
‘I  am  going  to  ask  you  some  questions  to  evaluate  your
emory.  Some  questions  are  very  easy  while  others  are  not
o  simple.  Try  to  give  the  best  answer.’’
Score/5  
.  What  is  today’s  year?............ 
.  What  season  it  is?................  
.  What  is  the  month?.............  
.  What  day  is  today?..............  
.  What  is  the  week?...............  
‘‘I  am  going  to  ask  you  now  some  questions  about  the
lace  we  are  in.’’
Score/5  
.  What  is  the  name  of  this
hospital?...........

.  What  city  are  we
in?............

.  In  what  department  is  this  city
situated?.  .  .. .  ... .  .. .  .. .  .. .  .. .  .. .  .. .  ...

.  In  what  region  is  this
department
situated?............

0.  What  ﬂoor  are  we  on?..........  mmediate recall
‘I  am  going  to  say  three  words.  Listen  carefully.  You  say
hem  back  after  I  stop.  Ready?  Here  they  are.’’O.  Hanon  et  al.
Score/3  
1.  Cigar................  
2.  Flower...........  
3.  Door............  
Now  repeat  those  words  back  to  me.
ttention and calculation
‘I  would  like  you  to  count  backwards  from  100  by  7.’’
Score/5  
4.  93..............  
5.  86..............  
6.  79..............  
7.  72..............  
8.  65..............  
For  all  subjects,  even  those  who  obtained  the  maximum
f  points,  ask  them  to  spell  the  word  ‘‘WORLD’’  backwards:
LROW.
The  score  corresponds  to  the  number  of  good  responses
this  ﬁgure  should  not  be  noted  in  the  ﬁnal  score).
ecall
‘Earlier  I  told  you  the  names  of  three  things.  Can  you  tell
e  what  those  were?’’
Score/3  
9.  Cigar............. 
0.  Flower............ 
1.  Door.............. 
anguage
Score/9  
2.  Show  a  pencil.  ‘What  is  the
name  of  this
subject?’.........................

3.  Show  a  wristwatch.  ‘What  is
the  name  of  this
subject?’................

4.  ‘Listen  carefully  and  repeat
the  phrase:  ‘no  ifs,  ands  or
buts’.’.......

Put a  sheet  of  blank  paper  on  the  desk,  show  it  to  the
ubject  and  then  say  ‘Listen  carefully  and  do  what  I  say.’
5.  ‘Take  the  paper  in  your  right
hand’.............

6. ‘Fold  it  in  half’..........  
7.  ‘And  put  it  on  the
ﬂoor’.............

8. Hold  up  the  card  that  reads
‘Close  your  eyes’  and  say  to
the  subject:
‘Read  it  and  do  what  it
says’.............

9.  Give  the  subject  a  sheet  of
blank  paper  and  a  pencil  and
ask  him  to  write  a  sentence;
it  should  contain  a  subject
and  a  verb,  and  is  sensible.
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Constructive praxia
30.  Show  the  subject  the  drawing
of  the  intersecting
pentagons.
‘Would  you  like  to  copy  this
drawing?’

Total  score  (0  to  30):  
Score  ≤  27,  suspicion  of  cognitive  impairment;
score  ≤  24,  suspicion  of  dementia.
Appendix 2. Memory Impairment Screen
(MIS) test [109].
‘I  am  going  to  show  you  some  words  written  on  this  sheet
of  paper.  Please  read  each  word  and  try  to  remember  it.’
LEEK  PLANE  TREE  WHITING  DAHLIA
‘Now,  I  would  like  you  to  count  from  1  to  20.’
When  the  patient  has  counted,  the  examiner  says:  ‘Can
you  tell  me  the  four  words  you  remember,  in  any  order.’
(free  recall)
If  the  patient  misses  a  word,  the  examiner  cues  the
patient  with  the  category:  e.g.  ‘There  was  also  a  tree,  what
was  this  tree?’  (cued  recall)
Immediate MIS
Count  2  points  for  each  item  recalled  without  cueing  (free
recall)  and  one  point  for  each  item  recalled  with  cue-
ing  (cued  recall).  The  score  equals  the  sum  of  free  +  cued
recall.
Free  recall
(2  points  per
recalled  word)
Cued  recall
(if  no  response  in
free  recall,  1
point  per
recalled  word)
Word
Leek
Plane
Whiting
DahliaScore
Total score = free recall + cued recall (maximum score = 8).
Cognitive disorder if score ≤ 6.
½
0319
elayed MIS
bout  10  minutes  later,  re-ask  the  patient  once  more  ‘Can
ou  tell  me  the  four  words  you  remember,  in  any  order.’
Free  recall
(2  points  per
recalled  word)
Cued  recall
(if  no  response  in
free  recall,  1  point
per  recalled  word)
ord
Leek
Plane
Whiting
Dahlia
core
otal score = free recall + cued recall (maximum score = 8).
ognitive disorder if score ≤ 6.
ppendix 3. Cognitive Disorders
xamination (CODEX) [110].
ODEX  is  a  simple  and  brief  test  for  detecting  dementia.  It
equires  at  least  3  minutes  to  administer.  It  can  be  conducted
y  non-specialized  persons  in  the  cognitive  assessment.
The  subject  is  asked  to  repeat  and  remember  three  words
cigar,  ﬂower  and  door).
The  evaluator  then  gives  the  subject  a  sheet  of  paper  on
hich  is  drawn  a  large  circle  (symbolizing  a  watch  face)  and
sks  him  to  write  the  numbers  of  hours  and  then  draw  the
ands  indicating  a  given  hour.  The  subject  is  then  asked  to
epeat  the  three  previously  memorized  words.
Lastly,  the  evaluator  asks  ﬁve  questions  about  spatial  ori-
ntation:  ‘What  street  (or  hospital)  are  we  in?  In  what  city?
n  which  department?  In  which  region?  On  what  ﬂoor?’
The  quotation  is  simple  and  a  binary  decisional  tree
llows  conclusion:  normal  CODEX  makes  the  likelihood  of
ementia  very  low;  conversely  if  CODEX  is  abnormal  the
robability  of  dementia  is  very  strong.
For  more  information  visit  the  website:  www.
estcodex.org.
ppendix 4. Katz Activities of Daily Living
ADL) scale [111].
athing
washbasin,  tub  or  shower  and  body  care)
   Needs  no  personal  assistance
   Needs  partial  assistance
   Dependency
ressing
get  clothes  from  closets  and  drawers  and  put  on  clothes  and
uter  garments  complete  with  fasteners)
   Needs  no  personal  assistance
   Gets  and  puts  clothes  without  help,
needs  help  with  tying  shoes.
   Dependency
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oileting
goes  to  toilet,  gets  on  and  off,  cleans  genital  area)
   Without  help
   Should  be  assisted  or  needs  help  for
getting  on  and  off
   Needs  help  transferring  to  the  toilet  or
uses  bedpan  or  commode.
ransferring
   Moves  in  and  out  of  bed  or  chair
unassisted.  Mechanical  transferring  aids
are  acceptable
   Needs  help
   Is  conﬁned  to  bed  (bedridden)
ontinence
   Exercises  complete  self  control  over
urination  and  defecation
   Is  partially  incontinent
   Is  totally  incontinent
eeding
   Without  help
   Needs  help  for  the  preparation  of  food
   needs  total  help
core/6:  
Normal  score  =  6/6)
ppendix 5. Four-item Instrumental
ctivities of Daily Living (IADL) scale
112].
.  Ability  to  use  telephone
  Operates  telephone  on  own  initiative;  looks  up
and  dials  numbers
. Mode  of  transportation
  Travels  independently  on  public  transportation
or  drives  own  car
.  Responsibility  for  own  medications
  Is  responsible  for  taking  medication  in  correct
dosages  at  correct  time
.  Ability  to  handle  ﬁnances
  Manages  ﬁnancial  matters  independently
(writes  cheques,  pays  rent,  bills,  goes  to  bank)
ach  item  is  scored  (0)  dependency  or  (1)  independency,
according  to  response.core/4:  
Normal  score  =  4/4)O.  Hanon  et  al.
ppendix 6. Mini Geriatric Depression
cale  (GDS) [113].
he  patient  is  asked  to  choose  the  best  answer  for  how  they
ave  felt  over  the  past  week.
.  Do  you  often  feel  sad  or  depressed?  Yes  =  1,  no  =  0
.  Do  you  feel  that  your  life  is  empty?  Yes  =  1,  no  =  0
.  Do  you  feel  happy  most  of  the  time? Yes  =  0,  no  =  1
.  Are  you  afraid  that  something  bad
is  going  to  happen  to  you?
Yes  =  1,  no  =  0
Results
f  total  score  =  0,  high  probability  of  absence  of  depression.
f  total  score  ≥  1,  high  probability  of  depression.
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